XOOMAR
Get a free API key

Pure Bioscience (PURE)

Pure Bioscience on one page: short interest, fails to deliver, earnings dates and insider trades. Listed on OTC.

Download CSV

19K

Short interest

settlement 2026-09-30

1.0

Days to cover

unchanged vs prior

103

Fails to deliver

settlement 2026-07-17

Wed 28 Oct

Next earnings

estimated date

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-09-30.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 30 September 2026, short interest in PURE is 19,268 shares, up 3,919 shares over the last month. Over the last 48 readings it ranged from 419 shares (29 November 2024) to 187,711 shares (15 May 2025). At the reported average volume of 80K shares a day that is 1.0 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pure" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-09-3019,268+15.1%79,7031.00
2026-09-1516,734+9.0%58,1211.00
2026-08-3115,349+52.0%68,0501.00
2026-08-1410,098+30.5%47,3221.00
2026-07-317,738+100.2%32,2761.00
2026-07-153,865-65.0%68,5961.00
2026-06-3011,031+191.0%30,2871.00
2026-06-153,791+4.1%43,6751.00
2026-05-293,641-25.4%92,0321.00
2026-05-154,878+2.5%24,2761.00
2026-04-304,758+49.1%72,7751.00
2026-04-153,191+0.0%136,2391.00
2026-03-313,191+4.1%84,8331.00
2026-03-133,066+3.4%89,1271.00
2026-02-272,966+0.0%61,4441.00
2026-02-132,966+1.1%10,9511.00
2026-01-302,934+0.9%54,9091.00
2026-01-152,909+0.0%44,8551.00
2025-12-312,909-88.9%131,0461.00
2025-12-1526,140+155.8%105,8771.00
2025-11-2810,219+252.9%148,1221.00
2025-11-142,896-35.5%154,4781.00
2025-10-314,492+55.1%63,8331.00
2025-10-152,896-29.4%45,4001.00
2025-09-304,102-86.2%126,0841.00
2025-09-1529,791+87.2%138,9251.00
2025-08-2915,914+57.3%124,0181.00
2025-08-1510,120+43.2%60,2111.00
2025-07-317,069+41.6%88,1961.00
2025-07-154,992-76.4%130,9961.00
2025-06-3021,140+3.0%6,1493.44
2025-06-1320,519-1.5%54,7071.00
2025-05-3020,826-88.9%202,1261.00
2025-05-15187,711+1251.1%104,4091.80
2025-04-3013,893+6.9%60,8741.00
2025-04-1512,991-34.3%97,7091.00
2025-03-3119,773+2144.4%163,1581.00
2025-03-14881+51.6%106,2171.00
2025-02-28581-98.4%59,8501.00
2025-02-1436,211+1743.7%35,3251.03
2025-01-311,964-93.3%119,9481.00
2025-01-1529,080+558.1%220,6131.00
2024-12-314,419+954.6%233,2311.00
2024-12-13419+0.0%105,7171.00
2024-11-29419-97.1%46,9121.00
2024-11-1514,515-68.8%80,5801.00
2024-10-3146,551+50.7%50,2771.00
2024-10-1530,892-47.2%24,0551.28

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 17 July 2026, the fails-to-deliver balance in PURE is 103 shares, unchanged over the last settlement date. Over the last 30 readings it ranged from 53 shares (15 July 2026) to 26,076 shares (20 August 2025). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-07-17103$0.06$6
2026-07-16103$0.06$6
2026-07-1553$0.06$3
2025-12-091,440$0.05$72
2025-12-08940$0.05$47
2025-09-236,757$0.09$608
2025-09-225,821$0.09$524
2025-09-1912,971$0.09$1K
2025-09-105,144$0.08$412
2025-09-095,374$0.08$430
2025-08-2026,076$0.09$2K
2025-08-195,877$0.09$529
2025-04-01445$0.09$40
2025-03-31445$0.09$40
2025-03-259,948$0.09$895
2025-02-07954$0.07$67
2025-01-308,900$0.07$623
2025-01-162,675$0.08$214
2025-01-152,675$0.07$187
2025-01-147,675$0.09$691
2025-01-094,375$0.08$350
2024-12-2311,250$0.09$1K
2024-12-2013,125$0.08$1K
2024-12-1914,125$0.06$848
2024-11-04348$0.11$38
2024-10-289,665$0.10$967
2024-05-291,400$0.10$140
2024-05-144,106$0.09$370
2024-05-134,106$0.10$411
2024-05-104,106$0.07$287

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for PURE in the last 90 days. The most recent filings are listed below. Latest filing: BARTLETT ROBERT F (CEO) on 2023-03-22.

DateInsiderTitleTypeSharesPriceValueOwned after
2023-03-22BARTLETT ROBERT FCEOBuy50K$0.16$8K50K
2023-03-21Blotner BernardDirectorBuy10K$0.13$1K10K
2022-12-15Lee Tom YChief Executive OfficerBuy50K$0.13$7K5.0M
2022-07-15Chen IvanDirectorGrant300K$0.15$45K750K
2022-07-15Lee Tom YChief Executive OfficerGrant15.7M$0.15$2.4M29.1M
2022-07-15Lee Tom YChief Executive OfficerGrant6.0M$0.15$900K6.0M
2022-07-15Rendall DavidDirectorGrant325K$0.15$49K402K
2022-03-21Lee Tom YChief Executive OfficerBuy185K$0.20$37K5.0M
2022-03-17Lee Tom YChief Executive OfficerBuy13K$0.18$2K4.8M
2022-03-16Lee Tom YChief Executive OfficerBuy21K$0.18$4K4.8M
2021-06-16Lee Tom YChief Executive OfficerBuy36K$0.43$15K4.7M
2020-12-24Lee Tom YChief Executive OfficerBuy851$0.65$5534.7M
2020-12-22Lee Tom YChief Executive OfficerBuy45K$0.66$30K4.7M
2020-12-21Lee Tom YChief Executive OfficerBuy8K$0.68$5K4.7M
2020-12-19Okuno DaleDirectorSell749K$0.29$217K5.6M
2020-12-17Lee Tom YChief Executive OfficerBuy5K$0.65$3K4.6M
2020-12-16Lee Tom YChief Executive OfficerBuy20K$0.67$13K4.6M
2020-06-24Lee Tom YChief Executive OfficerOther transaction10.7M$0.00$013.4M
2020-06-22Lee Tom YChief Executive OfficerBuy13K$1.72$23K4.6M
2020-06-19Lee Tom YChief Executive OfficerBuy10K$1.85$19K4.6M
2020-06-18Lee Tom YChief Executive OfficerBuy30K$1.75$53K4.6M
2020-06-17Lee Tom YChief Executive OfficerBuy27K$1.61$43K4.6M
2020-06-16Lee Tom YChief Executive OfficerBuy70K$1.62$113K4.5M
2020-06-15Lee Tom YChief Executive OfficerBuy60K$1.82$109K4.5M
2020-06-12Lee Tom YChief Executive OfficerBuy45K$1.91$86K4.4M
2020-05-01Myers Thomas RichardChief Operating OfficerGrant500K$0.00$0588K
2020-03-09Chen IvanDirectorGrant179K$0.29$52K450K
2020-03-09Lee Tom YDirectorGrant2.2M$0.29$650K24.1M
2020-03-09Okuno DaleDirectorGrant1.6M$0.29$450K7.1M
2020-02-14Lee Tom YDirectorGift1.0M$0.00$021.9M
2020-02-14Lee Tom YDirectorGift1.0M$0.00$01.0M
2019-12-31Okuno DaleDirectorSell40K$0.28$11K5.5M
2019-12-19Lee Tom YDirectorBuy755K$0.29$219K22.9M
2019-10-02Lee Tom YDirectorGrant1.0M$0.29$290K22.1M
2019-10-02Okuno DaleDirectorGrant862K$0.29$250K6.3M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

What this page is

Pure Bioscience in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Pure Bioscience (PURE), SEC CIK 1006028, listed on OTC. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-07-17.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-06-15.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2023-03-22.JSON and CSV
Company record
EDGAR filing index for CIK 1006028Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other company pages

Datasets

Frequently Asked Questions

How much of PURE is sold short?
19,268 shares were held short at the 2026-09-30 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PURE's daily short volume?
No daily short volume file lists PURE yet.
Does PURE have fails to deliver?
The SEC's latest file shows 103 PURE shares failed to deliver at settlement 2026-07-17. Fails are reported per settlement date and published twice a month with a lag.
Are PURE insiders buying or selling?
No open-market insider trades were reported for PURE in the last 90 days. The most recent filings are listed below. Latest filing: BARTLETT ROBERT F (CEO) on 2023-03-22.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.